Medicskin Holdings Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wir verfügen derzeit nicht über ausreichende Analystenabdeckung, um Wachstum und Umsatz für Medicskin Holdings zu prognostizieren.

Wichtige Informationen

n/a

Wachstumsrate der Gewinne

n/a

EPS-Wachstumsrate

Healthcare Gewinnwachstum	16.9%
Wachstumsrate der Einnahmen	n/a
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	None
Zuletzt aktualisiert	n/a

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

We Think Some Shareholders May Hesitate To Increase Medicskin Holdings Limited's (HKG:8307) CEO Compensation

Sep 15

Here's Why Shareholders May Want To Be Cautious With Increasing Medicskin Holdings Limited's (HKG:8307) CEO Pay Packet

Sep 16

Here's Why We Think Medicskin Holdings (HKG:8307) Is Well Worth Watching

Jul 18

Investor Optimism Abounds Medicskin Holdings Limited (HKG:8307) But Growth Is Lacking

Jun 11

A Look At The Fair Value Of Medicskin Holdings Limited (HKG:8307)

Feb 25

Shareholders Will Probably Hold Off On Increasing Medicskin Holdings Limited's (HKG:8307) CEO Compensation For The Time Being

Sep 15

Can Mixed Fundamentals Have A Negative Impact on Medicskin Holdings Limited (HKG:8307) Current Share Price Momentum?

Feb 11

Our Take On Medicskin Holdings' (HKG:8307) CEO Salary

Dec 16

In diesem Abschnitt stellen wir normalerweise Umsatz- und Gewinnwachstumsprognosen vor, die auf den Konsensschätzungen professioneller Analysten basieren, um den Anlegern zu helfen, die Fähigkeit des Unternehmens zur Gewinnerzielung zu verstehen. Da Medicskin Holdings jedoch nicht genügend Daten aus der Vergangenheit zur Verfügung gestellt hat und keine Analystenprognose vorliegt, können die zukünftigen Erträge nicht zuverlässig durch Extrapolation von Vergangenheitsdaten oder anhand von Analystenprognosen berechnet werden.

Dies ist eine recht seltene Situation, da 97 % der von SimplyWall St erfassten Unternehmen über Finanzdaten aus der Vergangenheit verfügen.

Gewinn- und Umsatzwachstumsprognosen

SEHK:8307 - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (HKD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
3/31/2024	50	-3	9	11	N/A
12/31/2023	51	-3	N/A	N/A	N/A
9/30/2023	51	-2	3	5	N/A
6/30/2023	49	-3	N/A	N/A	N/A
3/31/2023	46	-4	1	3	N/A
12/31/2022	41	-2	N/A	N/A	N/A
9/30/2022	43	-1	2	3	N/A
6/30/2022	46	2	N/A	N/A	N/A
3/31/2022	49	4	2	4	N/A
12/31/2021	49	1	N/A	N/A	N/A
9/30/2021	47	1	3	5	N/A
6/30/2021	45	2	N/A	N/A	N/A
3/31/2021	42	1	7	9	N/A
12/31/2020	42	1	N/A	N/A	N/A
9/30/2020	43	-1	10	12	N/A
6/30/2020	45	-2	N/A	N/A	N/A
3/31/2020	48	-3	13	15	N/A
12/31/2019	51	-3	N/A	N/A	N/A
9/30/2019	52	-3	9	12	N/A
6/30/2019	52	-5	N/A	N/A	N/A
3/31/2019	51	-5	0	4	N/A
12/31/2018	52	-2	N/A	N/A	N/A
9/30/2018	53	-1	-1	2	N/A
6/30/2018	55	1	N/A	N/A	N/A
3/31/2018	58	3	6	6	N/A
12/31/2017	61	3	N/A	N/A	N/A
9/30/2017	63	3	N/A	23	N/A
6/30/2017	63	3	N/A	N/A	N/A
3/31/2017	62	3	N/A	16	N/A
12/31/2016	60	3	N/A	N/A	N/A
9/30/2016	59	2	N/A	0	N/A
6/30/2016	58	2	N/A	N/A	N/A
3/31/2016	60	2	N/A	2	N/A
12/31/2015	62	4	N/A	N/A	N/A
9/30/2015	64	3	N/A	1	N/A
6/30/2015	65	3	N/A	N/A	N/A
3/31/2015	67	3	N/A	6	N/A
12/31/2014	68	2	N/A	N/A	N/A
3/31/2014	65	14	N/A	23	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: Unzureichende Daten, um festzustellen, ob das prognostizierte Gewinnwachstum von 8307 über der Sparquote liegt (2.2%).

Ertrag vs. Markt: Unzureichende Daten, um festzustellen, ob die Gewinne von 8307 schneller wachsen werden als der Markt Hong Kong

Hohe Wachstumserträge: Die Daten reichen nicht aus, um festzustellen, ob die Einnahmen von 8307 in den nächsten 3 Jahren signifikant steigen werden.

Einnahmen vs. Markt: Die Daten reichen nicht aus, um festzustellen, ob die Einnahmen von 8307 schneller wachsen werden als der Markt von Hong Kong.

Hohe Wachstumseinnahmen: Es liegen keine ausreichenden Daten vor, um festzustellen, ob die Einnahmen von 8307 schneller wachsen werden als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von 8307 in 3 Jahren voraussichtlich hoch sein wird

Medicskin Holdings Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Medicskin Holdings Limited Provides Unaudited Consolidated Earnings Guidance for Six Months Ended 30 September 2022

Medicskin Holdings Limited Provides Consolidated Earnings Guidance for the Three Months Ended June 30, 2022

Recent updates

Medicskin Holdings Limited, Annual General Meeting, Sep 06, 2024

Full year 2024 earnings released: HK$0.008 loss per share (vs HK$0.008 loss in FY 2023)

Now 34% overvalued after recent price rise

New minor risk - Financial data availability

Medicskin Holdings Limited to Report Fiscal Year 2024 Results on Jun 19, 2024

New minor risk - Share price stability

Now 20% overvalued after recent price rise

Now 23% undervalued after recent price drop

Second quarter 2024 earnings released: HK$0.004 loss per share (vs HK$0.006 loss in 2Q 2023)

New major risk - Market cap size

Medicskin Holdings Limited to Report Q2, 2024 Results on Nov 13, 2023

We Think Some Shareholders May Hesitate To Increase Medicskin Holdings Limited's (HKG:8307) CEO Compensation

Medicskin Holdings Limited Announces Appointment of Lui Sze On as Independent Non-Executive Director and Member of the Audit Committee, Remuneration Committee and Nomination Committee of the Board with Effect from September 6, 2023

New minor risk - Financial position

First quarter 2024 earnings released: HK$0.001 loss per share (vs HK$0.002 loss in 1Q 2023)

First quarter 2024 earnings released: HK$0.001 loss per share (vs HK$0.002 loss in 1Q 2023)

Medicskin Holdings Limited to Report Q1, 2024 Results on Aug 14, 2023

Medicskin Holdings Limited, Annual General Meeting, Sep 01, 2023

New minor risk - Share price stability

Full year 2023 earnings released: HK$0.007 loss per share (vs HK$0.01 profit in FY 2022)

Medicskin Holdings Limited Announces Resignation of Fu Frank Tsun Yin as Independent Non-Executive Director and A Member of the Audit Committee, Remuneration Committee and Nomination Committee

Medicskin Holdings Limited to Report Fiscal Year 2023 Results on Jun 21, 2023

Medicskin Holdings Limited Appoints Fu Frank Tsun Yin as an Independent Non-Executive Director and A Member of Each of the Audit Committee, Remuneration Committee and Nomination Committee of the Board with Effect from 14 February 2023

Third quarter 2023 earnings released: EPS: HK$0 (vs HK$0.004 in 3Q 2022)

Medicskin Holdings Limited to Report Q3, 2023 Results on Feb 13, 2023

Second quarter 2023 earnings released: HK$0.006 loss per share (vs HK$0.001 profit in 2Q 2022)

Medicskin Holdings Limited Announces Resignation of Lee Ka Lun as Independent Non-Executive Director and Member of the Audit Committee, Remuneration Committee and Nomination Committee

Less than half of directors are independent

Medicskin Holdings Limited Provides Unaudited Consolidated Earnings Guidance for Six Months Ended 30 September 2022

Medicskin Holdings Limited to Report First Half, 2023 Results on Nov 14, 2022

Here's Why Shareholders May Want To Be Cautious With Increasing Medicskin Holdings Limited's (HKG:8307) CEO Pay Packet

First quarter 2023 earnings released: HK$0.002 loss per share (vs HK$0.004 profit in 1Q 2022)

Medicskin Holdings Limited Provides Consolidated Earnings Guidance for the Three Months Ended June 30, 2022

Here's Why We Think Medicskin Holdings (HKG:8307) Is Well Worth Watching

Medicskin Holdings Limited, Annual General Meeting, Sep 23, 2022

Full year 2022 earnings released

Medicskin Holdings Limited, Annual General Meeting, Sep 23, 2022

Investor Optimism Abounds Medicskin Holdings Limited (HKG:8307) But Growth Is Lacking

Medicskin Holdings Limited to Report Fiscal Year 2022 Results on Jun 20, 2022

Less than half of directors are independent

Now 20% undervalued

A Look At The Fair Value Of Medicskin Holdings Limited (HKG:8307)

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Second quarter 2022 earnings released: EPS HK$0.001 (vs HK$0.002 in 2Q 2021)

Shareholders Will Probably Hold Off On Increasing Medicskin Holdings Limited's (HKG:8307) CEO Compensation For The Time Being

First quarter 2022 earnings released: EPS HK$0.004 (vs HK$0.002 in 1Q 2021)

Inaugural dividend of HK$0.025 per share

Full year 2021 earnings released: EPS HK$0.002 (vs HK$0.007 loss in FY 2020)

Medicskin Holdings Limited Announces Special Dividend for the Year Ended 31 March 2021, Payable on or around 26 July 2021

New 90-day high: HK$0.29

Can Mixed Fundamentals Have A Negative Impact on Medicskin Holdings Limited (HKG:8307) Current Share Price Momentum?

Third quarter 2021 earnings released: EPS HK$0.004 (vs HK$0.001 loss in 3Q 2020)

New 90-day high: HK$0.28

Medicskin Holdings Limited to Report Nine Months, 2021 Results on Feb 10, 2021

New 90-day high: HK$0.22

Our Take On Medicskin Holdings' (HKG:8307) CEO Salary

New 90-day high: HK$0.21

Second quarter 2021 earnings released: EPS HK$0.002

Medicskin Holdings Limited to Report First Half, 2021 Results on Nov 13, 2020

First quarter earnings released

Medicskin Holdings Limited to Report Q1, 2021 Results on Aug 14, 2020

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken